Novo Nordisk A/S
HealthcareNYSE:NVO · New York Stock Exchange
+$0.33 today
Vol 10.16M · Avg 16.14M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
52.8%
avg 136.3%
ROIC
29.5%
avg 112.0%
ROA
18.9%
avg 58.8%
Analysis
ROE is currently the strongest return metric at 52.8% versus its period average of 136.3%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Karsten Munk Knudsen | Executive Vice President, Chief Financial Officer & Member of the Management Board | $2.65M | — | 55 | — | — |
Martin Holst Lange | EVP of R&D, Chief Scientific Officer and Member of the Management Board | $1.88M | — | 56 | — | — |
Emil Kongshøj Larsen | EVP of International Operations & Member of Management Board | — | — | 51 | — | — |
Jamey Millar | Executive Vice President of US Operations & Member of Management Board | — | — | 58 | — | — |
John F. Kuckelman | SVP, Group General Counsel, Global Legal, IP & Security and Member of Management Board | — | — | 54 | — | — |
Maziar Mike Doustdar | President, Chief Executive Officer & Member of the Management Board | — | — | 56 | — | — |
Elin Jager | SVP, Chief of Staff to CEO, Corporate Strategy & Sustainability and Member of Management Board | — | — | 40 | — | — |
Hong Chow | Executive Vice President of Product & Portfolio Strategy and Member of Management Board | — | — | 55 | — | — |
Tania Sabroe | EVP of People, Organisation and Corporate Affairs & Member of Management Board | — | — | 49 | — | — |
Thilde Hummel Bogebjerg | Executive VP of Enterprise IT & Quality and Member of Management Board | — | — | 44 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +20.2% | +10.2% (15yr)6 analysts |
| Revenue | N/A | N/A | +11.4% | +8.8% (15yr)15 analysts |
| Net Income | N/A | N/A | +17.6% | +9.1% (15yr)15 analysts |
| EBIT | N/A | N/A | +18.8% | +9.0% (15yr)15 analysts |
Analysis
Recent growth has been strongest in EPS at +20.2% over three years. Forward estimates point to EPS at +10.2% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Merck & Co., Inc.
NYSE:MRK
$296.18B
Novartis AG
NYSE:NVS
$292.74B
AstraZeneca PLC
NYSE:AZN
$278.85B
Amgen Inc.
NASDAQ:AMGN
$190.79B
Thermo Fisher Scientific Inc.
NYSE:TMO
$174.66B
Gilead Sciences, Inc.
NASDAQ:GILD
$155.57B
Abbott Laboratories
NYSE:ABT
$152.81B
Pfizer Inc.
NYSE:PFE
$149.27B
GSK plc
NYSE:GSK
$106.58B
Sanofi
NASDAQ:SNY
$106.52B
Who manages NVO?
Novo Nordisk A/S (NVO) lists 10 active executives. The top listed executive is Martin Holst Lange, EVP of R&D, Chief Scientific Officer and Member of the Management Board.
Explore More
Continue the stock analysis
Jump to another research area for this company.